HETRASE study - Did heparin treatment benefit patients with ALI/ARDS?

Critical Care Medicine

Volumn 37, Issue 8, 2009, Pages 2490-

  Hofstra, Jorrit J ^a   Levi, Marcel ^a   Schultz, Marcus J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; D DIMER; HEPARIN;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; CLINICAL TRIAL; DRUG EFFICACY; HEPARINIZATION; HUMAN; LETTER; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK;

EID: 68249106282     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181ac4933     Document Type: Letter

References (7)

1. Jaimes F, De La Rosa G, Morales C, et al: Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med 2009; 37:1185-1196
2. Schultz MJ, Haitsma JJ, Zhang H, et al: Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia - A review. Crit Care Med 2006; 34: 871-877
3. Laterre PF, Garber G, Levy H, et al: Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33:952-961
4. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
5. Laterre PF, Opal SM, Abraham E, et al: A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (Tifacogin) in patients with severe community-acquired pneumonia. Crit Care 2009; 13:R36
6. Hofstra JJH, Juffermans NP, Schultz MJ, et al: Pulmonary coagulopathy as a new target in lung injury - A review of available pre-clinical models. Curr Med Chem 2008; 15:588-595
7. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-1349